Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

Sponsor
South Valley University
Study ID
NCT04519385
Status
Completed

Conditions

  • Pneumonia, Viral

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab therapy
  • Dexamethasone — DRUG
    dexamethsone pulse therapy

Study Details

randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19

Key Dates

Start date
Mar 1, 2020
Status verified
Aug 2020
Primary completion
Jul 1, 2020
Completion
Aug 5, 2020

Study Design

Enrollment
69 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tocilizumab
    Tocilizumab
  • Active Comparator: Dexamethasone
    Dexamethasone therapy

Primary Outcome Measure

Proportion of participants with Overall Survival at 14 days [ Time Frame: 14 days ]

Related Studies